PLAY PODCASTS
Beta Blockers in MI: Old Drug, New Lens, Possible Win πŸ”πŸ’₯πŸ₯

Beta Blockers in MI: Old Drug, New Lens, Possible Win πŸ”πŸ’₯πŸ₯

Dr RR Baliga's "Got Knowledge Doc" Podkast

August 31, 20254m 49s

Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

🚨 New NEJM Study Alert! πŸ©ΊπŸ’”

Do beta-blockers still help after a heart attack if there's no heart failure? πŸ€”

In the BETAMI–DANBLOCK trial (πŸ‡©πŸ‡°+πŸ‡³πŸ‡΄, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (β‰₯40%) modestly reduced the composite outcome of death or major cardiovascular events πŸ§ πŸ“‰

πŸ“Œ Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) β†’ HR 0.85, p=0.03

πŸ’‘ Especially lowered risk of recurrent MI (HR 0.73)

🧠 Even in the era of PCI, DAPT & statins, beta-blockers may still bring benefit β€” especially in patients with mildly reduced LVEF (40–49%) πŸ«€

πŸ”— [Add your slide link or DOI here]

#Cardiology #NEJM #HeartAttack #BetaBlockers #PostMI #EvidenceBasedMedicine #LVEF #PrecisionMedicine #ClinicalTrials